FATE THERAPEUTICS INC

FATESEC EDGAR

Biological Products, (No Diagnostic Substances)CIK: 1434316

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$13.6M	$63.5M	$96.3M	$31.4M	$10.7M
Research and Development Expense	$135.0M	$172.6M	$320.5M	$125.6M	$87.8M
Operating Expenses	$223.9M	$254.0M	$404.7M	$159.5M	$111.4M
Operating Income (Loss)	-$210.3M	-$190.5M	-$308.4M	-$128.1M	-$100.7M
Interest Expense	—	—	—	—	$1.8M
Other Nonoperating Income (Expense)	$24.0M	$29.6M	$26.7M	-$45.3M	$2.6M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$440.7M	$506.2M	$705.6M	$921.5M	$622.5M
Assets, Current	$291.9M	$331.5M	$502.1M	$633.4M	$494.3M
Cash and Cash Equivalents, at Carrying Value	$36.1M	$41.9M	$61.3M	$167.3M	$99.8M
Accounts Receivable, after Allowance for Credit Loss, Current	$3.5M	$1.8M	$38.5M	$8.7M	$5.5M
Liabilities, Current	$38.5M	$39.1M	$114.1M	$81.3M	$85.6M
Long-term Debt	—	—	—	—	—
Accounts Payable, Current	$9.4M	$4.7M	$8.3M	$8.6M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$122.9M	-$132.3M	-$248.2M	-$39.2M	-$83.2M
Net Cash Provided by (Used in) Investing Activities	$12.2M	$112.7M	$166.8M	-$161.1M	-$157.5M
Net Cash Provided by (Used in) Financing Activities	$99.9M	$85.0K	$9.2M	$282.8M	$149.9M
Payments to Acquire Property, Plant, and Equipment	$730.0K	$6.2M	$35.6M	$4.9M	$7.4M
Payments for Repurchase of Common Stock	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)